Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck? by Haerle, Stephan et al.
HEAD AND NECK
Is there a correlation between 18F-FDG-PET standardized uptake
value, T-classification, histological grading and the anatomic
subsites in newly diagnosed squamous cell carcinoma of the head
and neck?
Stephan K. Haerle • G. F. Huber • T. F. Hany •
N. Ahmad • D. T. Schmid
Received: 20 April 2010 / Accepted: 14 July 2010 / Published online: 3 August 2010
 Springer-Verlag 2010
Abstract 18F-Fluorodeoxyglucose (FDG) positron emis-
sion tomography/computed tomography (PET)/CT imaging
of squamous cell carcinoma of the head and neck
(HNSCC) renders the possibility to study metabolic tumor
activity by measuring FDG-uptake expressed as maximum
standardized uptake value (SUVmax). A correlation
between SUVmax and several factors including T-classifi-
cation, histological tumor differentiation or different ana-
tomic subsites is of potential interest in HNSCC. The aim
of this study was to evaluate how metabolic tumor activity
derived from FDG-PET correlates with prognostic clinical
and pathological parameters including these factors. 262
patients with HNSCC undergoing PET/CT for initial
staging were assessed separately for a potential correlation
between SUVmax and T-classification, histological grading,
and anatomical subsites of the primary tumor. Nonpara-
metric testing showed a significant correlation between
SUVmax and T-classification (P \ 0.001). On the contrary,
no statistically significant correlation was found between
SUVmax and histological tumor grading. Furthermore, no
statistical significant correlation between the different
anatomical subsites and SUVmax were found. There was no
significant correlation of SUVmax and tumor grading after
adjustment for T-stage and anatomical localization of the
tumor, neither. Conclusion: Metabolic tumor activity
correlates with T-stage of HNSCC. However, histological
tumor grading does not correlate with SUVmax. The role of
primary tumor SUVmax as a predictor of outcome or sur-
vival remains unclear. Clinicians should therefore exercise
caution in attributing any clinical importance to SUVmax
obtained from a single PET/CT exam.
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Introduction
Many different staging methods for squamous cell carci-
noma of the head and neck (HNSCC) have been described
over the last two decades. Clinical staging includes pan-
endoscopy and different imaging modalities, such as
computed tomography (CT) or magnetic resonance
imaging (MRI), both available at most institutions. Com-
bined functional and morphological imaging, such as
18F-Fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET)/CT for staging of HNSCC has shown
promising results recently [1–4]. In addition to conven-
tional morphological imaging using CT and MRI, PET
scanning allows for non-invasive study of tumor physiol-
ogy [5]. There is a correlation between the uptake of FDG
and the level of intracellular metabolic tumor activity,
which in turn may be associated with active proliferation,
invasion and incidence of loco-regional as well as distant
metastases [6]. To quantify the amount of FDG uptake
within a region of interest, the standardized uptake value
(SUV) is used most commonly, since the measurement is
standardized for injected activity, body weight and decay
time. Corresponding, correlation between SUVmax and
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several factors including T-classification, histological
tumor differentiation or different anatomic subsites is of
potential interest in HNSCC. Early detection of HNSCC
provides a significant survival advantage and the site of
primary disease is an important determinant of survival
for most cancers of the head and neck [7]. Recent studies
looked at different prognostic factors, whereas one of
the outmost important prognostic factors for surviving
HNSCC is the cervical lymph node involvement. Inter-
estingly, Chen et al. [8] reported a higher prevalence of
nodal metastases in elective neck dissections for poorly
differentiated carcinomas when compared to well-differ-
entiated tumors. Additionally, in a recent study Goerkem
et al. [9] looked at the rate of occult metastases in the
context of sentinel node biopsy: the less differentiated the
primary was, the higher was the risk for developing occult
metastases. Newer studies have included the maximum
SUV (SUVmax) in the context for predicting outcome for
patient suffering from HNSCC by looking at early SUV
pattern changes after multimodality treatment [6, 10]. In
their study, Suzuki et al. [10] also described a correlation
between the SUVmax and T-stage.
The aim of this study was to evaluate how metabolic
tumor activity (SUVmax) derived from FDG-PET correlates
with prognostic clinical and pathological parameters
including T-classification, histological tumor differentiation
or different anatomic subsites in HNSCC at the time point of
initial staging. This is important to understand if metabolic
information obtained from a single PET/CT exam has the
potential to serve as a predictor of disease outcome and
possibly influence initial treatment strategy or if it only helps
to differentiate benign from malignant changes.
Patients and methods
Two head and neck surgeons (HSK, HGF) reviewed the charts
of all patients presenting for initial treatment of a HNSCC
between November 2001 and December 2007, retrospec-
tively. A board-certified physician in both nuclear medicine
and radiology (SDT) reviewed records of all FDG-PET/CT
exams. A total of 294 patients with histological confirmed and
previously untreated HNSCC underwent FDG-PET/CT for
initial staging. All patients in our study granted permission for
anonymized evaluation of their medical data for scientific
purposes prior to PET/CT imaging.
This patient cohort does not represent a consecutive
group of all patients diagnosed with HNSCC within the
given time frame, because mainly patients with advanced
disease (T3/T4 and N2/N3, respectively) were referred for
FDG-PET/CT to search for loco-regional lymph node
metastases, distant metastases and synchronous malignant
tumors.
Imaging protocol
A combined PET/CT inline system (Discovery LS or
Discovery ST, GE Healthcare) was used for this study. This
device integrates a PET scanner (GE Advance Nxi; GE
Healthcare) with a multi-slice helical CT (LightSpeed Plus
or LightSpeed 16; GE Healthcare) and permits the acqui-
sition of co-registered CT and PET images in the same
session.
Patients fasted for at least 4 h prior to scanning, which
started 60 min after the injection of a standard dose of
approximately 350 MBq of FDG. An oral CT contrast
agent was given 75–60 min before scanning (150 mL,
Micropaque, Guerbet; diluted with 850 mL water). All
patients were examined in the supine position with arms
down. The CT scan was acquired during breath holding or
free shallow breathing. In the normal expiratory position,
the following parameters were used 140 kV, 80 mA, 0.5 s
tube rotation, 4.25-mm section thickness, a scan length of
867 mm with 22.5 s scan time. Acquisition of the FDG-
PET scan was started immediately after the CT with an
emission time of 3 min per table position resulting in a
total scan time of 18 min for 6 table positions from the
head to the pelvic floor.
CT data was used for attenuation correction. PET ima-
ges were reconstructed using a standard 2-dimensional
iterative algorithm [ordered subset expectation maximiza-
tion (OSEM)].
SUVmax analysis
A board-certified physician in both nuclear medicine and
radiology with 6 years experience in CT reading and
3 years experience in reading combined FDG-PET/CT in
head and neck cancer patients determined the SUVmax
retrospectively. Calculation of SUVmax was done using a
commercially available workstation (Advantage work-
station, software version 4.4, GE Healthcare). Before
measurement, a head and neck surgeon determined the
correct localization of the primary tumor retrospectively
based on the knowledge of intraoperative/invasive pro-
cedures performed after the PET/CT scan. A volume of
interest (VOI) was defined on screen that included the
FDG uptake related to the primary tumor on multiple
consecutive image sections. The value of the single
voxel with the highest activity within this VOI was used
for calculation of SUVmax (Fig. 1). The software pro-
vides this value automatically. All values were normal-
ized to the lean body mass (LBM) of the patient. The
use of LBW instead of body weight has been shown to
be less dependent on the body habitus of the study
population [11]. LBM was determined using a per-
sonal scale with an integrated foot-to-foot bioelectric
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impedance analyzer (Tanita model 2001; Tanita, Tokyo,
Japan).
Histological grading
The histological work-up of the primary was performed
according to the guidelines of the Swiss Society of Pathol-
ogy. All specimens were sectioned along the greatest
diameter and paraffin-embedded. Whole sections were
stained with hematoxylin–eosin, thus two surfaces per
biopsy were available. The specimens were subdivided into
well differentiated (1), moderately differentiated (2), and
poorly differentiated (3).
Statistical analysis
The entire cohort was analyzed according to the following
endpoints: the correlation between SUVmax and T-stage and
the potential correlation between SUVmax and the histolog-
ical grading with and without adjustment for anatomical
localization and T-stage. Furthermore, we have analyzed the
correlation between SUVmax and the anatomical subtype of
the primary. Nonparametric testing was used. P values\0.05
were considered significant. All calculations were carried
out using SPSS version 17.0 for windows.
Results
Clinical parameters
Between 2001 and 2007, a total number of 294 patients
were evaluated with FDG-PET/CT for a previously
untreated HNSCC. 17 patients were excluded due to
missing data for SUV calculation (lean body weight,
patient’s size, or injected activity), 2 patients were
excluded because of missing PET data, 1 patient was
excluded because of CUP (cancer of unknown primary)
syndrome, and 12 patients were excluded because the
primary tumor was not FDG avid in PET imaging (11
patients suffering from a T1 lesion, 1 patient suffering from
a T2 lesion). Finally, the number of 262 patients remained
for evaluation. There was a male predominance (n = 204,
78%). The mean age was 60.0 years (standard devia-
tion ± 10 years, range 36–90 years).
Localization and extension of the primary
In both male and female patients, the primary tumor was
predominantly located in the oropharynx (n = 144, 55%),
followed by the hypopharynx (n = 51, 19%), the larynx
(n = 33, 13%), the oral cavity (n = 30, 11%), and the
nasopharynx (n = 4, 2%). All patients presented in the
advanced stages III and IV [International Union against
Cancer (UICC) 1997]: n = 41 (16%) patients were staged
as stage III, n = 189 (72%) patients were staged as stage
IVa, and n = 32 (12%) patients were staged as stage IVb.
T- and N-stages of all tumors are shown in Table 1.
Histological differentiation of the primary tumors
Out of the 262 primary tumors, 15 (6%) were well-differ-
entiated SCC, 141 (54%) were moderately differentiated,
and 106 (40%) of all primary tumors were found to be
poorly differentiated.
Mean SUVmax values
SUVmax of all primaries was 10.7 (standard deviation ±4.6,
range 2.9–33.7). Mean SUVmax for the different anatomic
subsites, the different T-stages and histological gradings
are listed in Table 2.
Fig. 1 Axial (a), coronal (b) and sagittal (c) fused FDG-PET/CT
images of a 71-year old male patient with a newly diagnosed
oropharyngeal carcinoma illustrating the measurement of SUVmax:
the volume of interest (green rectangles) was set to enclose the whole
tumor. A threshold of 25% of the SUVmax was chosen to outline the
metabolic active tumor volume (green line within the green
rectangle). The software automatically determined the hottest voxel
within this volume (c, white arrow)
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Correlation between SUVmax and endpoints
Nonparametric testing using Kruskal–Wallis test showed a
significant correlation (P \ 0.001) of SUVmax and T-stage.
There was no statistically significant correlation of SUVmax
and histological grading (P = 0.232). Furthermore, no
significant differences were found for mean SUVmax of all
tumors of the same stage in relation to the anatomic subsite
of the primary tumor with P = 0.133 for T1 tumors
(n = 31), P = 0.626 for T2 tumors (n = 93), P = 0.578
for T3 tumors (n = 64) and P = 0.721 for T4 tumors
(n = 74). There was no significant correlation between the
different anatomic subsites and mean SUVmax (P = 0.646).
Furthermore, there was no significant correlation of
SUVmax and tumor grading after adjustment for T-stage
and anatomical localization of the tumor.
Discussion
FDG-PET/CT marks an essential tool for initial staging in
advanced HNSCC. Many important questions, such as the
presence of second primaries and distant metastases can be
answered at the time of diagnosis by using FDG-PET/CT
[2]. Therefore, FDG-PET/CT has a direct impact on ther-
apy decision and outcome [12]. Within the last few years,
the literature shows a growing tendency to take into
account metabolic information about the tumor when
planning treatment of HNSCC and predicting patient’s
outcome [13].
The aim of this study was to assess a correlation
between different clinical and pathological parameters and
SUVmax. This may play an important role regarding the
latest theories suggesting that FDG uptake of the primary
tumor is related to the treatment response, and survival in
HNSCC [14–17]. SUVmax is the most widely used
parameter to measure metabolic tumor activity in onco-
logic FDG-PET/CT imaging. According to Machtay et al.
[6] low SUVmax of the primary tumor was significantly
associated with longer disease-free survival after radio-
therapy of HNSCC in a series of 60 patients. On the con-
trary, Suzuki et al. [10] found no correlation between
SUVmax and treatment outcome in HNSCC after radio-
therapy in a series of 45 patients. Therefore, to elucidate
the role of SUVmax and its possible predictive role for
therapy response more distinguishable, the aim of this
retrospective analysis was to assess a potential correlation
between SUVmax and different clinical and pathological
Table 1 T- and N-stages of all
patients (n = 262) based on all
available clinical examination
including panendoscopy,
contrast-enhanced CT and PET/
CT
Data are numbers of subjects,
with percentages in parentheses
N0 N1 N2a N2b N2c N3 Total
T1 0 (0) 8 (3.1) 3 (1.1) 16 (6.1) 2 (0.8) 2 (0.8) 31 (11.8)
T2 0 (0) 10 (3.8) 0 (0) 66 (25.2) 12 (4.6) 5 (1.9) 93 (35.5)
T3 15 (5.7) 8 (3.1) 1 (0.4) 25 (9.5) 14 (5.3) 1 (0.4) 64 (24.4)
T4 11 (4.2) 10 (3.8) 2 (0.8) 23 (8.8) 23 (8.8) 5 (1.9) 74 (28.2)
Total 26 (9.9) 36 (13.7) 6 (2.3) 130 (49.6) 51 (19.5) 13 (5.0) 262 (100)
Table 2 Clinical characteristics
and correlations between
SUVmax and T-classification,
histological grading, and the
anatomic subsite
a Data are numbers of subjects,
with percentages in parentheses
b Data are means ± SD, with
range in parentheses
c Kruskal–Wallis test
Characteristics Patientsa SUVmax
b P value
T-stage
T1 31 (11.8) 8.3 ± 3.2 (3.0–21.8) \0.001c
T2 93 (35.5) 10.2 ± 4.5 (2.9–24.7)
T3 64 (24.4) 11.0 ± 4.3 (4.0–23.6)
T4 74 (28.2) 11.9 ± 4.8 (3.4–33.7)
Histological grading
Well differentiated 15 (5.7) 12.0 ± 4.1 (3.8–16.4) 0.232c
Moderately differentiated 141 (53.8) 10.4 ± 4.4 (2.9–33.7)
Poorly differentiated 106 (40.5) 10.9 ± 5.0 (3.7–29.9)
Anatomical subsite
Nasopharynx 4 (1.5) 11.5 ± 2.2 (8.3–13.3) 0.646c
Oral cavity 30 (11.5) 11.4 ± 4.4 (3.4–23.6)
Oropharynx 144 (55.0) 10.4 ± 4.5 (2.9–33.7)
Hypopharynx 51 (19.5) 10.7 ± 5.0 (3.8–24.7)
Larynx 33 (12.6) 11.4 ± 5.1 (4.1–29.9)
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parameters at initial staging in a large patient cohort. First,
a positive correlation between SUVmax and T-stage can be
shown (P \ 0.001). In other words: the higher the T-stage,
the higher the SUVmax. This is in accordance with other
authors [10, 15, 18, 19]. A recent study in 627 patients with
oropharyngeal carcinoma identified higher T-stage as a
prognostic factor for poorer local control [20]. With regard
to the histological grading of HNSCC and SUVmax no
statistical correlation was found in our series (P = 0.232).
This is in accordance to the findings of Suzuki et al. [10].
However, SUVmax values greater than 16.4 were only
observed in 24 moderately and poorly differentiated tumors
in our series of patients but not in well differentiated
tumors (Fig. 2). The idea to look at this potential correla-
tion lies in the fact of the helpful discriminating ability of
FDG-PET/CT in the evaluation of grading of soft-tissue
sarcoma [21]. Furthermore, survival is improved in patients
with differentiated tumors as compared to those with
poorly differentiated tumors [22]. However, summarizing
our results within a relatively large patient cohort
(n = 262), we did not find any correlation between histo-
pathological aggressiveness and SUVmax. Nevertheless,
there are authors proposing a cutoff SUV value of 9 cor-
relating with worse survival [19]. The last parameter we
looked at was the anatomic subsite of HNSCC. Again, no
significant correlation between SUVmax and tumor subsite
was found (P = 0.646). To us, this is not surprising since a
T3 tonsillar carcinoma with avid FDG uptake is not com-
parable to a T3 carcinoma of the larynx where FDG uptake
may not be as high due to the different definitions of a T3
tumor at different subsites. Further studies are needed to
assess the possible value of SUVmax as a predictive factor
of treatment outcome in HNSCC.
Conclusion
Metabolic tumor activity measured with FDG-PET/CT and
expressed as SUVmax correlates with T-stage of HNSCC.
However, histological tumor grading does not correlate
with SUVmax. The role of primary tumor SUVmax as a
predictor of outcome or survival remains unclear. Clini-
cians should therefore exercise caution in attributing any
clinical importance to SUVmax obtained from a single PET/
CT exam.
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